BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,300 From $1,082, Outperform Rating Maintained
Regeneron Pharmaceuticals Analyst Ratings
UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating
Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183
Regeneron Pharmaceuticals Analyst Ratings
Barclays Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $1200
Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,050
RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,232 From $1,229, Keeps Outperform Rating
Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook
Regeneron Pharmaceuticals Analyst Ratings
Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Maintains $1152 Price Target
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,170 From $1,060, Buy Rating Maintained
RBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1229 Price Target
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $1,150 From $1,050
Wells Fargo Adjusts Price Target on Regeneron Pharmaceuticals to $1,125 From $1,050
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115